- Celiac Disease & Gluten Intolerance Research
Celiac Disease & Gluten Intolerance Research
A gluten-free diet is till the only treatment for celiac disease, but a number of companies are working on pharmaceutical treatments. However, very little information exists bout the level of interest among patients in using a medication to treat celiac disease.
A team of researchers recently set out to assesses the safety and efficacy of Aspergillus niger prolyl endoprotease (AN–PEP) to mitigate the effects of gluten in celiac patients.
People with non-celiac gluten-sensitivity often report gut and non-gut symptoms shortly after eating gluten; symptoms disappear on gluten-free diets, although these patients have no serologic markers of celiac disease, and no intestinal damage. However, there is no evidence to suggest any changes to blood or mucosa in those individuals.
A team of researchers recently investigated the specific effects of gluten after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates (fermentable, oligo-, di-, monosaccharides, and polyols [FODMAPs]) in patients with suspected non-celiac gluten sensitivity (NCGS).
There is evidence that certain types of gut trauma can trigger celiac disease, but almost nothing is know about whether traumatic brain injury might trigger a neurological form of celiac disease in some individuals.
A team of researchers recently set out to study the prevalence of dental enamel defects in adults with celiac disease, and to determine if there is in fact a connection between the grade of teeth lesion and clinical parameters present at the time of diagnosis of celiac disease.
Researchers say a new, hairless variety of canary seeds bred specifically for human consumption would make an ideal gluten-free cereal for people with celiac disease.
A research team finds that the current standard practice of screening adolescents who are either symptomatic or at high-risk for celiac disease proves to be more cost-effective than universal screening.
Celiac disease is known to be caused by a combination of genetic and environmental factors. The genetic markers are fairly well established by now, but the environmental factors that are associated with celiac disease are still pretty foggy. A recent study suggests that antibiotic use might be one such factor.
Australian food manufacturers and retailers are pushing the government agency that regulates gluten-free food to allow gluten to be included in foods labeled ''gluten-free.''
In an effort to find a way other than these invasive methods to distinguish between uncomplicated and complicated forms of celiac disease, a research team set out to study serum parameters in the spectrum of celiac disease
Researchers have completed a genetic study of six autoimmune diseases, including diabetes, the largest such study of human disease genetics to date.
Potential celiac disease (PCD) is a type of celiac disease marked by positive endomysial/tissue transglutaminase antibodies and a preserved duodenal mucosa despite a gluten-containing diet (GCD). PCD can turn into active celiac disease, but very little is currently known about what causes that to happen.
Hoping to develop a vaccine that will allow patients with celiac disease to safely eat gluten, researchers are busily exploring the possibilities offered therapeutic vaccines, known as antigen-specific immunotherapy.
To investigate the prevalence of human leukocyte antigen (HLA) DQ2/8 alleles in Southern Italians with liver and gastrointestinal (GI) diseases outside of celiac disease, a team of researchers recently looked at human leukocyte antigen DQ2/8 prevalence in non-celiac patients with gastrointestinal diseases.
Researchers have known for some time that immunoglobulin G antibodies against deamidated gliadin peptides are about as accurate as tissue transglutaminase and endomysium autoantibodies in diagnosing celiac disease in adults. However, not much is known about their predictive value in infants with a suspected gluten enteropathy.
A number of studies have indicated that people with celiac disease have an inadequate response to hepatitis B vaccination. In an effort to better understand the issue, a team of researchers assessed hepatitis B vaccination response in relation to gluten exposure status in patients with celiac disease.
Intestinal absorption capacity is currently regarded as the best way to assess overall digestive intestinal function. Earlier reference values for intestinal function in healthy Dutch adults were based on a study that was conducted in an inpatient metabolic unit setting in a relatively small series.
Previous studies have shown an immunologic response primarily directed against transglutaminase (TG)6 in patients with gluten ataxia (GA). A team of researchers set out to see if Transglutaminase 6 antibodies could be helpful in the diagnosis of gluten ataxia.
A team of researchers recently set out to test determine if an interactive online intervention might help to improve gluten free diet adherence in adults with celiac disease.